Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.67 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181893 | 1.00 | AKR1C3 (0.67) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| SCHEMBL2585302 | 1.00 | AKR1C3 (0.67) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7565316 | 0.98 | AKR1C3 (0.64) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7565312 | 0.98 | AKR1C3 (0.64) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| SCHEMBL1842887 | 0.94 | AKR1C3 (0.60) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| SCHEMBL3860890 | 0.93 | AKR1C3 (0.58) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| Guanidine SCHEMBL7163058 | 0.89 | AKR1C3 (0.55) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| Guanidine SCHEMBL7163063 | 0.89 | AKR1C3 (0.55) | AKR1C3TRPA1ABCB11SIGMAR1ALDH1A1 | |
| SCHEMBL2462983 | 0.89 | AKR1C3 (0.82) | AKR1C3ALDH1A1HTTPOLBTBXAS1 | |
| SCHEMBL2462984 | 0.89 | AKR1C3 (0.82) | AKR1C3ALDH1A1HTTPOLBTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115537194-A | Ligand modified quantum dot, quantum dot film, preparation method of quantum dot film and light-emitting device | TCL科技集团股份有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-109896684-B | Sewage pretreatment process in organic product preparation process | 李德祥 | 2021-12-24 | — | — | CN | claimed |
| EP-2571497-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | Sanford-Burnham Medical Research Institute (US) | 2013-03-27 | — | — | EP | claimed |
| CN-103002887-A | Methods and compositions relating to retinoid receptor selective pathways | SANFORD BURNHAM MED RES INST | 2013-03-27 | — | — | CN | claimed |
| WO-2011140525-A2 | METHODS AND COMPOSITIONS RELATED TO A RETINOID RECEPTOR-SELECTIVE PATHWAY | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-11-10 | — | — | WO | claimed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-4110322-A1 | SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAS) AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115537194-A | Ligand modified quantum dot, quantum dot film, preparation method of quantum dot film and light-emitting device | TCL科技集团股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| CN-109896684-B | Sewage pretreatment process in organic product preparation process | 李德祥 | 2021-12-24 | — | — | CN | disclosed |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | ADT PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| EP-0508586-B1 | Substituted indenyl compounds | FGN INC (US) | 1995-05-31 | — | — | EP | disclosed |
| EP-0654025-A1 | METHOD OF PREPARING OPTICALLY PURE PRECURSORS OF PAROXETINE | SEPRACOR, INC. (US) | 1995-05-24 | — | — | EP | disclosed |
| US-5401774-A | Treatment of potentially cancerous growths | UNIVERSITY OF ARIZONA (US) | 1995-03-28 | — | — | US | disclosed |
| WO-1994003428-A1 | METHOD OF PREPARING OPTICALLY PURE PRECURSORS OF PAROXETINE | SEPRACOR, INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| US-5258517-A | Method of preparing optically pure precursors of paroxetine | SEPRACOR, INC. (US) | 1993-11-02 | — | — | US | disclosed |
| EP-0508586-A1 | Substituted indenyl compounds | FGN, INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| EP-0485172-A2 | Esters and amides of substituted indenyl acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0350012-A2 | Antiviral composition | MEIJI SEIKA KAISHA LTD. (JP) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | AKR1C3 532/4885TRPA1 1897/4885ABCB11 62/4885 |
| US-11198679-B2 | Method of treating or preventing Ras-mediated diseases | KRAS, NRAS, HRAS | AKR1C3 381/4885TRPA1 4773/4885ABCB11 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.